Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Haleon PLC Sponsored ADR ( (HLN) ).
On September 4, 2025, Haleon PLC announced the purchase and cancellation of 354,000 ordinary shares as part of the second tranche of its share buyback program initiated on July 31, 2025. This transaction, conducted on September 3, 2025, reflects Haleon’s strategic move to manage its share capital and potentially enhance shareholder value, impacting the company’s market positioning and stakeholder interests.
The most recent analyst rating on (HLN) stock is a Hold with a $10.50 price target. To see the full list of analyst forecasts on Haleon PLC Sponsored ADR stock, see the HLN Stock Forecast page.
Spark’s Take on HLN Stock
According to Spark, TipRanks’ AI Analyst, HLN is a Neutral.
Haleon PLC’s overall stock score reflects a strong financial position and operational improvements, particularly in international markets. However, challenges in North America and stagnant revenue growth weigh on the score. Technical indicators and valuation suggest moderate potential for growth, with no significant corporate events impacting the assessment.
To see Spark’s full report on HLN stock, click here.
More about Haleon PLC Sponsored ADR
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with humanity. The company offers a diverse product portfolio across six major categories: Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Haleon is known for its long-standing, trusted brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren.
Average Trading Volume: 11,534,421
Technical Sentiment Signal: Buy
Current Market Cap: $43.7B
See more insights into HLN stock on TipRanks’ Stock Analysis page.